pharma · Asthma · Type 2 Diabetes
AstraZeneca
AstraZeneca is a pharma organization headquartered in Södertälje, SE. Primary therapeutic focus areas include Asthma, Type 2 Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease,
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 129
- Drugs
- 77
- Patents
- 25
MEDI4736 (Durvalumab)
Phase 3 · mab · Non-Small-Cell Lung Carcinoma NSCLC
MEDI4736 (Durvalumab) for Non-Small-Cell Lung Carcinoma NSCLC is a Phase 3 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Internal code D419AC00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca
- Phase
- Phase 3
- Modality
- mab
- Indication
- Non-Small-Cell Lung Carcinoma NSCLC
- Status
- active
- Trials
- 1